Syndax Pharmaceuticals Inc. (SNDX) Now Covered by Analysts at Guggenheim
Separately, Zacks Investment Research raised shares of Syndax Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, June 16th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Syndax Pharmaceuticals presently has an average rating of Buy and a consensus price target of $25.80.
Syndax Pharmaceuticals (NASDAQ:SNDX) traded up 1.612% during midday trading on Friday, reaching $15.445. The company’s stock had a trading volume of 10,774 shares. The firm has a 50 day moving average price of $14.37 and a 200 day moving average price of $13.49. The firm’s market cap is $274.64 million. Syndax Pharmaceuticals has a one year low of $8.97 and a one year high of $18.03.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 9th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Equities research analysts forecast that Syndax Pharmaceuticals will post ($3.01) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Cormorant Asset Management LLC bought a new stake in Syndax Pharmaceuticals during the first quarter worth about $2,856,000. BlackRock Group LTD bought a new stake in Syndax Pharmaceuticals during the first quarter worth about $2,379,000. Jennison Associates LLC increased its stake in Syndax Pharmaceuticals by 16.6% in the second quarter. Jennison Associates LLC now owns 537,545 shares of the company’s stock worth $5,247,000 after buying an additional 76,653 shares during the period. BlackRock Inc. bought a new stake in Syndax Pharmaceuticals during the first quarter worth about $594,000. Finally, Tiverton Asset Management LLC bought a new stake in Syndax Pharmaceuticals during the first quarter worth about $3,846,000. 57.64% of the stock is currently owned by institutional investors and hedge funds.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Stock Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.